# Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

> **NCT01203917** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1060 (actual)

## Conditions studied

- Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

## Interventions

- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT01203917
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2012-08
- **Final completion:** 2016-06
- **Target enrollment:** 1060 (ACTUAL)
- **Last updated:** 2017-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01203917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01203917, "Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01203917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*